middle.news
How Invex’s Exenatide Breakthrough Could Transform Alzheimer’s Treatment
8:32am on Monday 11th of August, 2025 AEST
•
Healthcare
Read Story
How Invex’s Exenatide Breakthrough Could Transform Alzheimer’s Treatment
8:32am on Monday 11th of August, 2025 AEST
Key Points
FY25 net loss narrowed to $476,868 from $1.64 million in FY24
R&D expenses dropped sharply following Phase III trial closure
New collaboration with Tessara Therapeutics yields encouraging Alzheimer’s disease model results
Strong cash position of $5.38 million maintained
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
IXC
OPEN ARTICLE